Regeneron Pharmaceuticals (REGN) Total Liabilities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Total Liabilities of $10.0 billion for Q2 2026, up 21.0% year-over-year from $8.3 billion in Q2 2025, and up 6.08% quarter-over-quarter from $9.4 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Total Liabilities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $10.0 billion for Q2 2026.
- In Q2 2026, Total Liabilities rose 21.0% year-over-year to $10.0 billion; the TTM figure through Jun 2026 stood at $10.0 billion (up 21.0% YoY), while the FY2025 annual figure was $9.3 billion, up 10.66% from the prior year.
- Total Liabilities for Q2 2026 stood at $10.0 billion, up from $9.4 billion in the prior quarter.
- The five-year high for Total Liabilities was $10.0 billion in Q2 2026, with the low at $6.2 billion in Q3 2022.
- The 5-year median for Total Liabilities is $7.6 billion (2024), against an average of $7.8 billion.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities decreased 2.72% in 2022, then gained 21.0% in 2026.
- Regeneron Pharmaceuticals' Total Liabilities stood at $6.6 billion in 2022, then rose by 8.5% to $7.1 billion in 2023, then gained by 18.27% to $8.4 billion in 2024, then advanced by 10.66% to $9.3 billion in 2025, then gained by 7.71% to $10.0 billion in 2026.
- Business Quant data shows REGN's Total Liabilities at $10.0 billion in Q2 2026, $9.4 billion in Q1 2026, and $9.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.02 Bn |
| Mar 31, 2026 | 9.45 Bn |
| Dec 31, 2025 | 9.30 Bn |
| Sep 30, 2025 | 9.21 Bn |
| Jun 30, 2025 | 8.28 Bn |
| Mar 31, 2025 | 8.16 Bn |
| Dec 31, 2024 | 8.41 Bn |
| Sep 30, 2024 | 8.12 Bn |
| Jun 30, 2024 | 7.88 Bn |
| Mar 31, 2024 | 7.38 Bn |
| Dec 31, 2023 | 7.11 Bn |
| Sep 30, 2023 | 7.26 Bn |
| Jun 30, 2023 | 6.64 Bn |
| Mar 31, 2023 | 6.56 Bn |
| Dec 31, 2022 | 6.55 Bn |
| Sep 30, 2022 | 6.24 Bn |
| Jun 30, 2022 | 6.52 Bn |
| Mar 31, 2022 | 6.43 Bn |
| Dec 31, 2021 | 6.67 Bn |
| Sep 30, 2021 | 6.41 Bn |